trending Market Intelligence /marketintelligence/en/news-insights/trending/cIWFxY9LR_p4zN5511CcKg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Genocea granted extension to regain compliance with Nasdaq listing requirement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Genocea granted extension to regain compliance with Nasdaq listing requirement

Genocea Biosciences Inc. was granted an additional 180 calendar days, or until June 11, 2019, by Nasdaq to regain compliance with the exchange's $1 minimum bid price listing requirement.

Previously, the Cambridge, Mass.-based biopharmaceutical company was given until Dec. 12 to regain compliance for continued listing on Nasdaq.

Genocea became eligible for the extension period after it determined it will not be in compliance by Dec. 12 and submitted an application to transfer its securities from listing on the Nasdaq Global Market to the Nasdaq Capital Market.

As a result, Genocea's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market at business open on Dec. 17. The company's common stock will continue to trade under the symbol GNCA.

Genocea Biosciences develops vaccines and immunotherapies to treat infectious diseases and cancer.